Regional cerebral tau predicts decline in everyday functioning across the Alzheimer’s disease spectrum
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Regional cerebral tau predicts decline in everyday functioning across the Alzheimer’s disease spectrum ; volume:15 ; number:1 ; day:5 ; month:7 ; year:2023 ; pages:1-8 ; date:12.2023
Alzheimer's research & therapy ; 15, Heft 1 (5.7.2023), 1-8, 12.2023
- Urheber
-
Dubbelman, Mark A.
Mimmack, Kayden J.
Sprague, Emily H.
Amariglio, Rebecca E.
Vannini, Patrizia
Marshall, Gad A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-023-01267-w
- URN
-
urn:nbn:de:101:1-2023100408304927223011
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dubbelman, Mark A.
- Mimmack, Kayden J.
- Sprague, Emily H.
- Amariglio, Rebecca E.
- Vannini, Patrizia
- Marshall, Gad A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum
Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau
Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
APOE effects on regional tau in preclinical Alzheimer’s disease
Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum
Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau
Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
APOE effects on regional tau in preclinical Alzheimer’s disease
Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum
Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau
Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease